Invention Grant
- Patent Title: Soluble tumor necrosis factor receptor mutant
- Patent Title (中): 可溶性肿瘤坏死因子受体突变体
-
Application No.: US12745724Application Date: 2009-01-12
-
Publication No.: US08454969B2Publication Date: 2013-06-04
- Inventor: Yanjun Liu , Tong Yang , Yijun Shen , Jinsong Wu , Fang Wu
- Applicant: Yanjun Liu , Tong Yang , Yijun Shen , Jinsong Wu , Fang Wu
- Applicant Address: CN Shanghai CN Jiangsu
- Assignee: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.,Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd.
- Current Assignee: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.,Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Shanghai CN Jiangsu
- Agency: Novak Druce Connolly Bove + Quigg LLP
- Priority: CN200810038410 20080530
- International Application: PCT/CN2009/000037 WO 20090112
- International Announcement: WO2009/143689 WO 20091203
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.
Public/Granted literature
- US20110117082A1 Soluble Tumor Necrosis Factor Receptor Mutant Public/Granted day:2011-05-19
Information query
